Dedicated and empathetic Nurse Practitioner with a strong commitment to delivering high-quality care and fostering open lines of communication with both patients and the healthcare team. Years of nursing experience, calm and understanding demeanor enable effective evaluation, research, and treatment of various medical conditions through thorough physical examinations and testing. Exceptional critical thinking and decision-making skills for informed judgments in complex situations. Board-certified Family Nurse Practitioner deeply committed to building strong relationships with patients and their families, acting as their advocate for the best possible outcomes.
· ACCTTION Multi-Site Observational Study-Further refine the NIDA PhABPhenotype Battery with specific attention paid to sub-typing participant characteristics in order to create better treatments for substance users in the future. The goal is for this battery to be efficiently embedded into future clinical trials.
· CTN 0109 CURB2 Multi-Site Phase IIB Investigational Product: Randomized, Placebo Controlled Trial of Extended-Release of Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder.
· CTN 0110 MURB Multi-Site Phase IIB Investigational Product: Randomized, Double-Blind, Placebo-Controlled Trial of Monthly Injectable Buprenorphinefor Methamphetamine Use Disorder.
· CTN-0048 CURB Phase III Investigational Product: Cocaine Use Reduction with Buprenorphine
· CTN-0053 ACCENT Phase III Investigational Product- Achieving Cannabis Cessation-Evaluating N-AcetylcysteineTreatment
· CTN-0054 ADAPT Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder. A 2-stage, 3-site study investigating the safety and effectiveness of depot naltrexone(XR-NTX; as Vivitrol®) plus extended-release bupropion(BRP; as Wellbutrin XL®) for methamphetamine use disorder.
· IMSTI- Behavioral Treatment, Contingency Management Study: Impact of Methamphetamine Use and Rectal STIs on Systemic and Rectal MucosalInflammation.
· NIDA/VA CSP-1036-Naltrexone-Bupropion Study: Randomized, Placebo-Controlled, Multi-Site Trial of Extended-Release Naltrexone Injection/Bupropion XL Tablets in the Treatment of Methamphetamine Use Disorder
· Purpose 2 Phase III Investigational Product: A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People ≥ 16 years of Age who Have Sex with Male Partners and are at Risk for HIV infection.
· TV1380-COA-201 TEVA Pharmaceutical Industries Phase II Investigational Product: A 12-week multicenterrandomized double-blind placebo controlled, parallel group study to evaluate the Efficacy and Safety of Once-weekly intramuscular injections of TV-1380 (150mg/week or 300mg/week) as treatment for facilitation of abstinence in cocaine-dependent subjects.